A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the orally-administered phosphodiesterase 9 (PDE9) inhibitor, CRD-750, targeting both ...

Left bundle branch block may serve as an important indicator for asymptomatic individuals predisposed to heart failure.

New FDA Indication: Kerendia (finerenone) is now approved to reduce cardiovascular death, heart failure (HF) hospitalization, and urgent HF visits in adults with HF and left ventricular ejection ...

Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...

The incretin-based therapies reduced mortality and hospitalization risk in individuals with heart failure with preserved ...

A tiny implantable heart device is changing lives for patients with HFpEF heart failure. Scripps La Jolla is among 65 ...

For the HF patient with a gain in LVEF, there’s little guidance on how best to care for them or manage their GDMT.

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...